In Brief This Week: Sigma-Aldrich; CLC Bio; Exiqon; Adaptive TCR; Evogene | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Leerink Swann downgraded Sigma-Aldrich to Market Perform from Outperform and reduced its target share price on the firm to a range of between $66 and $70. The bank lowered the EPS estimate for Sigma for full-year 2011 to $3.76 from $3.77. The lower estimates reflect a challenging academic funding environment as well as European macro-environment, an analyst said in a research note.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.